Skip to main content
Premium Trial:

Request an Annual Quote

UC, San Diego Selected as Site for Benitec HCV Drug Trial

Premium

Benitec Biopharma this week announced that the University of California, San Diego, has been selected as another site of the company’s phase I/II trial of the expressed RNAi-based hepatitis C treatment TT-034.

Last month, the company said that the Duke Clinical Research Unit would also be a site for the trial (GSN 3/28/2013).

The trial is designed to evaluate single escalating doses of the drug in patients with chronic HCV genotype I infection who have failed previous treatment, Benitec said.

It is expected to enroll 14 patients in five sequential dose cohorts, with the possibility of additional cohorts to confirm study findings. Endpoints include safety, as well as serum viral load reduction and hepatocyte transduction levels.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.